文献速递垂体与肾上腺疾病

无功能肾上腺肿瘤患者的精神与睡眠障碍风险

Psychiatric and Sleep Disorders in Patients With Nonfunctional Adrenal Tumors.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

结果显示NFAT患者既往精神/睡眠障碍患病率更高(调整OR 2.06,95%CI 1.98-2.14),随访期间发病率亦更高(调整HR 1.92,95%CI 1.82-2.01),所有次要结局及敏感性分析方向一致。

要点

  • NFAT患者精神/睡眠障碍患病风险约为对照的2倍。
  • 随访期间新发精神/睡眠障碍风险亦增加近1倍。
  • 该关联在多项敏感性分析中保持一致。

核心结论

  • 无功能肾上腺肿瘤与精神及睡眠障碍风险增加相关。

研究设计与样本

  • 排除肾上腺激素过多或既往恶性肿瘤者,随访自NFAT诊断后无癌生存90天开始至死亡或2019年。

主要发现

  • NFAT患者既往精神/睡眠障碍患病率高于对照(OR 2.11,95%CI 2.03-2.19;调整OR 2.06,95%CI 1.98-2.14)。
  • 随访中位5.4年期间,NFAT患者精神/睡眠障碍发病率高于对照(HR 1.92,95%CI 1.83-2.02;调整HR 1.92,95%CI 1.82-2.01)。
  • 所有次要结局及敏感性分析均显示相同方向的增加。

临床怎么用

  • 对NFAT患者应关注精神及睡眠障碍的筛查与评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: An increase of psychiatric and sleep-related disorders could be hypothesized due to mild abnormal cortisol secretion in patients with nonfunctional adrenal tumors (NFATs). OBJECTIVE: To investigate the risk of psychiatric and sleep disorders in individuals with NFATs. METHODS: A national retrospective register-based study was conducted on patients diagnosed with NFATs 2005-2019 and controls, followed until death or 2019. Individuals diagnosed with adrenal hormone excess or previous malignancies were excluded. Follow-up commenced after 90 days of cancer-free survival following the NFAT diagnosis. Sensitivity analyses were performed on patients with acute appendicitis and gallbladder/biliary tract/pancreas disorders, and 180- and 365-day cancer-free survival. The primary study outcomes were the prevalence and incidence of psychiatric and/or sleep disorders after adjusting for sex, age, and socioeconomic factors. Secondary outcomes were psychiatric, sleep, substance abuse, mood, anxiety and stress-related, and psychotic disorders. RESULTS: In total, 17 561 cases (60% women, median [IQR] age 65 [56-73] years) and 122 561 controls were included. Previous psychiatric and/or sleep disorders were more prevalent in patients diagnosed with NFATs compared to controls (odds ratio [OR] 2.11; 95% CI 2.03-2.19; adjusted OR 2.06, 95% CI 1.98-2.14). During the follow-up period (5.4 years [IQR 2.4-8.6]), the incidence of psychiatric and/or sleep disorders was higher in patients with NFATs than in controls (hazard ratio [HR] 1.92; 95% CI 1.83-2.02; adjusted HR 1.92; 95% CI 1.82-2.01). Similar increases were found in all secondary outcomes as well as in the same direction in all sensitivity analyses. CONCLUSION: NFAT was associated with an increased risk of psychiatric and sleep disorders.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Mirzaei H, Lindh JD, Mannheimer B, et al. Psychiatric and Sleep Disorders in Patients With Nonfunctional Adrenal Tumors. J Clin Endocrinol Metab. 2026. PMID: 40973669. doi:10.1210/clinem/dgaf525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。